Autolus Therapeutics plc Share Price & Technical Analysis
AUTL · $1.70 (+3.03%)
Healthcare / Biotechnology
$1.70
+3.03%
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-ce…
Price chart
Seasonality
May has 4 positive and 1 negative years (last 5 years shown)
21% return in May, 38% avg return in past 3 year May month.
-5% return in 2026, 29% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -30% | 21% | -18% | 0% | 21% | – | – | – | – | – | – | – | -5% |
| 25 | -8% | -23% | -12% | -12% | 29% | 28% | 4% | -35% | 7% | -6% | -12% | 43% | 1% |
| 24 | -5% | -2% | 7% | -41% | 14% | -17% | 34% | -19% | -8% | -6% | -3% | -32% | -77% |
| 23 | 10% | -10% | -10% | -5% | 72% | -23% | 33% | 0% | -28% | 22% | 54% | 49% | 164% |
| 22 | -23% | -7% | 14% | -26% | -13% | 4% | 0% | 18% | -34% | 27% | -10% | -30% | -82% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Emerging · Uptrend
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$415.02M
P/E ratio
—
52W high
$2.70
52W low
$1.18
Volume
10,43,463
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Autolus Therapeutics plc share price today?
- Autolus Therapeutics plc (AUTL) last traded around $1.70 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does AUTL have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for AUTL. Download the app for real-time alerts.
- How can I analyze Autolus Therapeutics plc stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.